These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 28114846)
21. Vaginal micronized progesterone and risk of preterm delivery in high-risk twin pregnancies: secondary analysis of a placebo-controlled randomized trial and meta-analysis. Klein K; Rode L; Nicolaides KH; Krampl-Bettelheim E; Tabor A; Ultrasound Obstet Gynecol; 2011 Sep; 38(3):281-7. PubMed ID: 21739499 [TBL] [Abstract][Full Text] [Related]
22. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. Kaandorp SP; Goddijn M; van der Post JA; Hutten BA; Verhoeve HR; Hamulyák K; Mol BW; Folkeringa N; Nahuis M; Papatsonis DN; Büller HR; van der Veen F; Middeldorp S N Engl J Med; 2010 Apr; 362(17):1586-96. PubMed ID: 20335572 [TBL] [Abstract][Full Text] [Related]
23. Hydroxychloroquine for prevention of recurrent miscarriage: study protocol for a multicentre randomised placebo-controlled trial BBQ study. Pasquier E; de Saint-Martin L; Marhic G; Chauleur C; Bohec C; Bretelle F; Lejeune-Saada V; Hannigsberg J; Plu-Bureau G; Cogulet V; Merviel P; Mottier D BMJ Open; 2019 Mar; 9(3):e025649. PubMed ID: 30898821 [TBL] [Abstract][Full Text] [Related]
24. Luteal phase support with progesterone in intrauterine insemination: a prospective randomized study. Romero Nieto MI; Lorente González J; Arjona-Berral JE; Del Muñoz-Villanueva M; Castelo-Branco C Gynecol Endocrinol; 2014 Mar; 30(3):197-201. PubMed ID: 24397361 [TBL] [Abstract][Full Text] [Related]
25. A feasibility trial of screening women with idiopathic recurrent miscarriage for high uterine natural killer cell density and randomizing to prednisolone or placebo when pregnant. Tang AW; Alfirevic Z; Turner MA; Drury JA; Small R; Quenby S Hum Reprod; 2013 Jul; 28(7):1743-52. PubMed ID: 23585559 [TBL] [Abstract][Full Text] [Related]
26. Assessment of sub-endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent miscarriage: a pilot study. Ghosh S; Chattopadhyay R; Goswami S; Chaudhury K; Chakravarty B; Ganesh A J Obstet Gynaecol Res; 2014 Jul; 40(7):1871-6. PubMed ID: 25056464 [TBL] [Abstract][Full Text] [Related]
28. Oral dydrogesterone versus vaginal progesterone gel in the luteal phase support: randomized controlled trial. Tomic V; Tomic J; Klaic DZ; Kasum M; Kuna K Eur J Obstet Gynecol Reprod Biol; 2015 Mar; 186():49-53. PubMed ID: 25622239 [TBL] [Abstract][Full Text] [Related]
29. A Phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization. Tournaye H; Sukhikh GT; Kahler E; Griesinger G Hum Reprod; 2017 May; 32(5):1019-1027. PubMed ID: 28333318 [TBL] [Abstract][Full Text] [Related]
30. Combined oral prednisolone and heparin versus heparin: the effect on peripheral NK cells and clinical outcome in patients with unexplained recurrent miscarriage. A double-blind placebo randomized controlled trial. Gomaa MF; Elkholy AG; El-Said MM; Abdel-Salam NE Arch Gynecol Obstet; 2014 Oct; 290(4):757-62. PubMed ID: 24818590 [TBL] [Abstract][Full Text] [Related]
31. Does a short luteal phase correlate with an increased risk of miscarriage? A cohort study. Duane M; Schliep K; Porucznik CA; Najmabadi S; Stanford JB BMC Pregnancy Childbirth; 2022 Dec; 22(1):922. PubMed ID: 36482355 [TBL] [Abstract][Full Text] [Related]
32. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double-blind, placebo-controlled trial. DeFranco EA; O'Brien JM; Adair CD; Lewis DF; Hall DR; Fusey S; Soma-Pillay P; Porter K; How H; Schakis R; Eller D; Trivedi Y; Vanburen G; Khandelwal M; Trofatter K; Vidyadhari D; Vijayaraghavan J; Weeks J; Dattel B; Newton E; Chazotte C; Valenzuela G; Calda P; Bsharat M; Creasy GW Ultrasound Obstet Gynecol; 2007 Oct; 30(5):697-705. PubMed ID: 17899571 [TBL] [Abstract][Full Text] [Related]
33. Progestogens and pregnancy loss. Carp HJA Climacteric; 2018 Aug; 21(4):380-384. PubMed ID: 29565684 [TBL] [Abstract][Full Text] [Related]
34. Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia. HABENOX: a randomised multicentre trial. Visser J; Ulander VM; Helmerhorst FM; Lampinen K; Morin-Papunen L; Bloemenkamp KW; Kaaja RJ Thromb Haemost; 2011 Feb; 105(2):295-301. PubMed ID: 21103659 [TBL] [Abstract][Full Text] [Related]
35. Can we alter pregnancy outcome by adjusting progesterone treatment at mid-luteal phase: a randomized controlled trial. Aslih N; Ellenbogen A; Shavit T; Michaeli M; Yakobi D; Shalom-Paz E Gynecol Endocrinol; 2017 Aug; 33(8):602-606. PubMed ID: 28277886 [TBL] [Abstract][Full Text] [Related]
36. The role of progesterone in maternal and fetal medicine. Di Renzo GC; Giardina I; Clerici G; Mattei A; Alajmi AH; Gerli S Gynecol Endocrinol; 2012 Nov; 28(11):925-32. PubMed ID: 23057618 [TBL] [Abstract][Full Text] [Related]
37. The cost-effectiveness of progesterone in preventing miscarriages in women with early pregnancy bleeding: an economic evaluation based on the PRISM trial. Okeke Ogwulu CB; Goranitis I; Devall AJ; Cheed V; Gallos ID; Middleton LJ; Harb HM; Williams HM; Eapen A; Daniels JP; Ahmed A; Bender-Atik R; Bhatia K; Bottomley C; Brewin J; Choudhary M; Deb S; Duncan WC; Ewer AK; Hinshaw K; Holland T; Izzat F; Johns J; Lumsden M; Manda P; Norman JE; Nunes N; Overton CE; Kriedt K; Quenby S; Rao S; Ross J; Shahid A; Underwood M; Vaithilingham N; Watkins L; Wykes C; Horne AW; Jurkovic D; Coomarasamy A; Roberts TE BJOG; 2020 May; 127(6):757-767. PubMed ID: 32003141 [TBL] [Abstract][Full Text] [Related]
38. A practical approach to the prevention of miscarriage: Part 1--Progesterone therapy. Check JH Clin Exp Obstet Gynecol; 2009; 36(4):203-8. PubMed ID: 20101845 [TBL] [Abstract][Full Text] [Related]